86847-74-7

Basic information

• Product Name: 2-(TERT-BUTYL)-1H-PYRROLO[2,3-B]PYRIDINE
• Synonyms: 2-(TERT-BUTYL)-7-AZAINDOLE;2-(TERT-BUTYL)-1H-PYRROLO[2,3-B]PYRIDINE;1H-Pyrrolo[2,3-b]pyridine, 2-(1,1-dimethylethyl)-
• CAS NO: 86847-74-7
• Molecular Formula: C₁₁H₁₄N₂
• Molecular Weight: 174.24
• Mol File: 86847-74-7.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 304.3°Cat760mmHg
• Flash Point: 127.8°C
• Appearance: /
• Density: 1.076g/cm³
• Vapor Pressure: 0.00159mmHg at 25°C
• Refractive Index: 1.595
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 2-(TERT-BUTYL)-1H-PYRROLO[2,3-B]PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(TERT-BUTYL)-1H-PYRROLO[2,3-B]PYRIDINE(86847-74-7)
• EPA Substance Registry System: 2-(TERT-BUTYL)-1H-PYRROLO[2,3-B]PYRIDINE(86847-74-7)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 86847-74-7(Hazardous Substances Data)

Usage

General Description

2-(tert-butyl)-1H-pyrrolo[2,3-b]pyridine is a chemical compound with a fused heterocyclic structure containing a pyrrolopyridine ring system. It is commonly used in organic synthesis and pharmaceutical research as it exhibits potential biological activities. The tert-butyl group attached to the nitrogen atom in the pyrrolopyridine ring provides steric hindrance, which may affect its reactivity and biological properties. 2-(TERT-BUTYL)-1H-PYRROLO[2,3-B]PYRIDINE may have applications in the development of new drugs and materials due to its unique structural features and potential pharmacological activities. Further research is needed to fully understand the properties and potential uses of 2-(tert-butyl)-1H-pyrrolo[2,3-b]pyridine.

InChI:InChI=1/C11H14N2/c1-11(2,3)9-7-8-5-4-6-12-10(8)13-9/h4-7H,1-3H3,(H,12,13)

Upstream product

• 630-18-2 tert-butyl isocyanide 
• 108-99-6 3-Methylpyridine 
• 86847-66-7 2,2-dimethyl-N-(3-methylpyridin-2-yl)propionamide 
• 504-29-0 2-aminopyridine 
• 113975-22-7 2-fluoro-3-iodopyridine 
• 917-92-0 3,3-Dimethylbut-1-yne 
• 1603-40-3 3-methylpyridin-2-ylamine 
• 13534-99-1 2-Amino-3-bromopyridine 
• 75-97-8 3,3-dimethyl-butan-2-one 
• 3282-30-2 pivaloyl chloride 
• 113975-31-8 N-(3-iodopyridin-2-yl)-2,2-dimethylpropionamide 
• 86847-59-8 2-(pivaloylamino)pyridine 
• 24331-71-3 N,N-dimethylpivalamide 
• 113975-39-6 2,2-dimethyl-N-<3-(3,3-dimethyl-2-oxobutyl)-2-pyridinyl>propanamide 

Downstream Products

• 1014613-61-6 4-bromo-2-(1,1-dimethylethyl)-1H-pyrrolo[2,3-b]pyridine 
• 1312891-51-2 (E)-3-(4-{[2-(2-tert-butyl-1H-pyrrolo[2,3-b]pyridin-3-yl)ethylamino]methyl}phenyl)-N-hydroxyacrylamide 
• 1312891-89-6 (E)-3-(4-{[2-(2-tert-butyl-1H-pyrrolo[2,3-b]pyridin-3-yl)ethylamino]methyl}phenyl)acrylic acid methyl ester 
• 1049676-91-6 2-tert-butyl-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde 

Relevant articles and documents

AZAINDOLES AND METHODS OF USE THEREOF

Disclosed are compounds according to Formula (I) or (II), and pharmaceutical compositions comprising them. Also disclosed are therapeutic methods, e.g., of treating kidney diseases, using the compounds of Formula (I) or (II). (Formulae (I, (II))

Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors

Histone deacetylase (HDAC) inhibitors have shown promise in treating various forms of cancer. However, many HDAC inhibitors from diverse structural classes have been associated with QT prolongation in humans. Inhibition of the human ether a-go-go related gene (hERG) channel has been associated with QT prolongation and fatal arrhythmias. To determine if the observed cardiac effects of HDAC inhibitors in humans is due to hERG blockade, a highly potent HDAC inhibitor devoid of hERG activity was required. Starting with dacinostat (LAQ824), a highly potent HDAC inhibitor, we explored the SAR to determine the pharmacophores required for HDAC and hERG inhibition. We disclose here the results of these efforts where a high degree of pharmacophore homology between these two targets was discovered. This similarity prevented traditional strategies for mitigating hERG binding/modulation from being successful and novel approaches for reducing hERG inhibition were required. Using a hERG homology model, two compounds, 11r and 25i, were discovered to be highly efficacious with weak affinity for the hERG and other ion channels.

NOVEL COMPOUNDS

The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds according to formula (I) and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular IKK2 activity.